Agreement on supply of Molybenum 99 to US medical imaging market

NorthStar Medical Radioisotopes LLC has signed an agreement with Triad Isotopes Inc to establish the first commercially viable US source of molybdenum-99 (Mo-99), the most widely used radioisotope in medical diagnostic imaging. Under the agreement, NorthStar will work with Triad Isotopes to bring non-uranium-based Mo-99 produced with its proprietary RadioGenix isotope separation system to market.  NorthStar, is developing a US source of Mo-99 produced without the use of highly enriched uranium (HEU) to help alleviate chronic shortages of the vital medical isotope.  Mo-99 is the parent isotope of technetium-99m (Tc-99m), which is used in millions of nuclear medicine procedures annually. Key applications include myocardial perfusion imaging, sentinel node mapping, hepatobiliary imaging  and inflammation and infection imaging. Currently, almost all Mo-99 is produced using highly enriched uranium at aging facilities located outside of the United States, leading to product shortages. NorthStar has two methods of producing Mo-99 without using highly enriched uranium, both of which produce only a benign waste stream.


NorthStar Medical Radioisotopes LLC

Madison, WI, USA